Please login to the form below

Are patient recruitment and retention rates rising or falling?

First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise.

The Tufts Center for the Study of Drug Development (CSDD) collected data on 87 clinical trials from four top-20 pharma companies and one global CRO, comparing the 2019 metrics from 2012. And they found some amazing results:

  • Actual enrolment exceeded planned enrolment in 2019 by 113%, compared to 2012 when trials achieved an average of only 96% of planned enrolment
  • Sites are recruiting faster, with 77% of trials now hitting or beating planned timelines, compared to only 47% previously
  • Trials in North America had the highest planned-to-actual enrolment ratio vs the rest of the world
  • Both North American and Asia/Pacific trials achieved an activation rate of more than 85%
  • Of all sites studied, 87% of proposed early-stage trials, and 85.7 percent of late-stage trials, were able to begin recruiting
  • Respondents’ average number of sites activated in 2019 was 30.5 in North America, 30.1 in Eastern Europe, 27 in Western Europe and 12.5 in Asia/Pacific.

Amazing, right? And according to CSDD, patient involvement in protocol development, mobile data collection devices and virtual trials all contributed to improved recruitment metrics since 2012. It just shows that all the hard work we’re doing as an industry to improve patient recruitment strategies really is paying off.

The hard truth

But, the bad news? Retention rates are falling.

When comparing the 2019 metrics from 2012, CSDD found:
  • In 2019, trial dropout rate rose to 19.1% from 15.3% in late-stage trials globally, with the highest rates occurring in central nervous system (CNS) and oncology trials
  • CNS trial dropout rates grew to 25.9% from 19.2
  • Oncology trial rates grew to 19.3% from 18.2%
  • Vaccine trials experienced a 12.3% dropout rate in 2019
  • Cardiovascular and rare disease trials fared best, with rates of 7% and 6.5% respectively

So, it looks like while recruitment rates have been on the up, this hasn’t translated over to retention. This does make sense when you consider that some companies work so hard to get participants onto their trial in the first place; it can often be forgotten to work on the rest of the patient experience too. And the hard truth is, just because more patients are signing up to take part in a clinical study, there’s nothing stopping them from leaving. So, that’s why retention strategies are just as important as recruitment.

Onwards and upwards

With retention rates taking a serious hit according to the CSDD study, it’s time to make a change. Luckily, there are ways that you can make the experience better for patients and help them want to stay on the study. Here at COUCH Health, we can help you with strategies to do this. Take a look at our white paper to learn more.

This blog was originally published here.

24th September 2020



Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Suite 2.10, Jactin House
24 Hood Street
M4 6WX
United Kingdom

Latest content on this profile

#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history.
COUCH Health
#DemandDiversity: The science behind diversity
We’re going back to the basics to explain why it’s so important for us to make a change.
COUCH Health
5 reasons clinical trial drop-out rates are on the rise
According to a recent report by the CSDD, patient recruitment rates have been steadily increasing, which is great news! The study found that 77% of clinical trials are now either meeting or exceeding their enrolment targets, in comparison to just 47% in 2012.
COUCH Health
#DemandDiversity: Names erased from history: A dive into black history of clinical research
You might be aware that February is Black History Month in the United States. So, we wanted to take the time to highlight some monumental moments and figures in the black history of clinical trials and medical research and share these with you
COUCH Health
How media portrayal of clinical trials can lead to underrepresentation
We knew that ethnic minority communities were being disproportionately affected by COVID-19, and we also knew that ethnic minorities were underrepresented in COVID-19 clinical trials. What we don’t know, however, is why ethnic minority groups weren’t taking part. So, we decided to do some digging.
COUCH Health
Can cultural safety training for sites improve diversity?
Through our Demand Diversity project, we’ve researched how the public is perceiving the industry during a time of heightened awareness, with a large focus on the perspectives of ethnic minority groups and key workers.
COUCH Health